- Home
- CRESY vs QURE Comparison
CRESY vs QURE Comparison
Compare CRESY & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRESY
- QURE
- Stock Information
- Founded
- CRESY 1936
- QURE 1998
- Country
- CRESY Argentina
- QURE Netherlands
- Employees
- CRESY N/A
- QURE N/A
- Industry
- CRESY Real Estate
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- CRESY Finance
- QURE Health Care
- Exchange
- CRESY Nasdaq
- QURE Nasdaq
- Market Cap
- CRESY 815.5M
- QURE 750.6M
- IPO Year
- CRESY 1997
- QURE 2007
- Fundamental
- Price
- CRESY $12.75
- QURE $15.76
- Analyst Decision
- CRESY
- QURE Strong Buy
- Analyst Count
- CRESY 0
- QURE 8
- Target Price
- CRESY N/A
- QURE $30.43
- AVG Volume (30 Days)
- CRESY 340.2K
- QURE 4.5M
- Earning Date
- CRESY 02-07-2025
- QURE 11-05-2024
- Dividend Yield
- CRESY 7.68%
- QURE N/A
- EPS Growth
- CRESY N/A
- QURE N/A
- EPS
- CRESY N/A
- QURE N/A
- Revenue
- CRESY $751,941,316.00
- QURE $28,587,000.00
- Revenue This Year
- CRESY N/A
- QURE $150.65
- Revenue Next Year
- CRESY N/A
- QURE N/A
- P/E Ratio
- CRESY N/A
- QURE N/A
- Revenue Growth
- CRESY N/A
- QURE N/A
- 52 Week Low
- CRESY $6.56
- QURE $3.73
- 52 Week High
- CRESY $14.23
- QURE $17.71
- Technical
- Relative Strength Index (RSI)
- CRESY 53.57
- QURE 74.36
- Support Level
- CRESY $13.12
- QURE $6.11
- Resistance Level
- CRESY $14.11
- QURE $17.71
- Average True Range (ATR)
- CRESY 0.70
- QURE 1.42
- MACD
- CRESY -0.11
- QURE 0.91
- Stochastic Oscillator
- CRESY 28.50
- QURE 83.50
About CRESY Cresud S.A.C.I.F. y A.
Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.